Literature DB >> 8532153

Modulation of sensory neurone excitatory and inhibitory responses in the ventrobasal thalamus by activation of metabotropic excitatory amino acid receptors.

T E Salt1, S A Eaton.   

Abstract

Several different types of metabotropic excitatory amino acid receptors (mGluRs) are present in the thalamus. We have previously shown that the agonists L-AP4 and CCG-I can have apparently presynaptic effects on GABAergic inhibitory transmission in the thalamus. In this study we attempted to characterize the different receptor types which may mediate these effects and the known post-synaptic excitatory actions of 1S,3R-ACPD in the ventrobasal thalamus, by using a number of agonists with different spectra of activity at the various mGluRs. Inhibitory responses in ventrobasal thalamic neurones of urethane-anaesthetized rats were evoked by air-jet stimuli to the vibrissae and extracellular recording methods were used to reveal inhibitory responses as an inhibition of excitatory responses in a condition-test paradigm. The Group II and Group III mGluR agonists L-AP4, CCG-I, DCG-IV, 1S,3R-ACPD and S-4C3HPG, applied in the vicinity of the recording site by iontophoresis, were found to reduce inhibitions revealed by the condition-test paradigm (by 67, 75, 50, 43 and 77% from control inhibitions, respectively). The endogenous mGluR agonist L-serine-O-phosphate (L-SOP) was found to have similar, although weaker, actions (31% reduction of inhibition), while the Group I agonist 3,5-DHPG had little effect in this test (9% reduction of inhibition). In contrast, both 3,5-DHPG and 1S,3R-ACPD had direct excitatory actions on VB neurones, and these could be antagonized by 4CPG. The effects of CCG-I in the condition-test paradigm could be antagonized by the antagonists MCCG, MCPG, but not MAP4.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8532153     DOI: 10.1016/0028-3908(95)00052-8

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Positive allosteric modulation reveals a specific role for mGlu2 receptors in sensory processing in the thalamus.

Authors:  C S Copeland; S A Neale; T E Salt
Journal:  J Physiol       Date:  2011-12-23       Impact factor: 5.182

Review 2.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

3.  Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7.

Authors:  G Sansig; T J Bushell; V R Clarke; A Rozov; N Burnashev; C Portet; F Gasparini; M Schmutz; K Klebs; R Shigemoto; P J Flor; R Kuhn; T Knoepfel; M Schroeder; D R Hampson; V J Collett; C Zhang; R M Duvoisin; G L Collingridge; H van Der Putten
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 4.  Glutamate and Its Receptors as Therapeutic Targets for Migraine.

Authors:  Jan Hoffmann; Andrew Charles
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

5.  Epileptogenesis in vivo enhances the sensitivity of inhibitory presynaptic metabotropic glutamate receptors in basolateral amygdala neurons in vitro.

Authors:  V Neugebauer; N B Keele; P Shinnick-Gallagher
Journal:  J Neurosci       Date:  1997-02-01       Impact factor: 6.167

6.  Temporal summation of heat pain in humans: Evidence supporting thalamocortical modulation.

Authors:  Tuan D Tran; Heng Wang; Animesh Tandon; Luis Hernandez-Garcia; Kenneth L Casey
Journal:  Pain       Date:  2010-05-21       Impact factor: 6.961

Review 7.  The function of metabotropic glutamate receptors in thalamus and cortex.

Authors:  S Murray Sherman
Journal:  Neuroscientist       Date:  2013-03-04       Impact factor: 7.519

8.  Neuronal activity patterns in the mediodorsal thalamus and related cognitive circuits are modulated by metabotropic glutamate receptors.

Authors:  C S Copeland; S A Neale; T E Salt
Journal:  Neuropharmacology       Date:  2015-01-07       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.